Spyryx Biosciences Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Out of Business

Spyryx Biosciences General Information

Description

Operator of a privately held, clinical-stage biopharmaceutical company intended to create innovative therapeutics to address severe lung diseases. The company's therapeutics utilizes inhaled peptides to treat severe pulmonary diseases where mucus accumulation and obstructions are key to disease progression, enabling healthcare institutes to get peptide for the treatment of orphan lung and respiratory diseases like Cystic Fibrosis and Chronic Obstructive Pulmonary Disorder.

Contact Information

Formerly Known As
Spyryx
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • 801-10 Capitola Drive
  • Durham, NC 27713
  • United States
+1 (919) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spyryx Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Sep-2019 000.00 Completed Out of Business
3. Later Stage VC 04-Oct-2018 000.00 000.00 Completed Clinical Trials - Phase 2
2. Grant 20-Jun-2017 $5M $18.2M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 24-Apr-2015 $18.2M $18.2M 000.00 Completed Product Development
To view Spyryx Biosciences’s complete valuation and funding history, request access »

Spyryx Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Spyryx Biosciences’s complete cap table history, request access »

Spyryx Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a privately held, clinical-stage biopharmaceutical company intended to create innovative therapeutics to add
Pharmaceuticals
Durham, NC
10 As of 2017
000.00
00000000 00 000.00

000000

mmodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000000
London, United Kingdom
00 As of 0000
00.000
000000000 00 00.000

000000

nsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000 000000000
San Francisco, CA
00 As of 0000
00000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spyryx Biosciences Competitors (78)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verona Pharma Private Debt Financed London, United Kingdom 00 00.000 000000000 00 00.000
Theravance Biopharma Corporation San Francisco, CA 00 000000&0
The Zambon Group Private Debt Financed Bresso, Italy 0000 000.00 000000000 000.00
Edesa Biotech Formerly VC-backed Markham, Canada 00 0000 000000000 0000
Rallybio Formerly VC-backed New Haven, CT 00 00000 00000000 00000
You’re viewing 5 of 78 competitors. Get the full list »

Spyryx Biosciences Patents

Spyryx Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3554527-A1 Saline formulations of splunc1 peptides Inactive 13-Dec-2016 000000000
CA-3046361-A1 Saline formulations of splunc1 peptides Inactive 13-Dec-2016 000000000
US-20200031866-A1 Peptide inhibitors of sodium channels Inactive 29-Sep-2016 000000000
US-9796768-B2 Peptide inhibitors of sodium channels Inactive 08-Oct-2014 00000000 00
US-20160102121-A1 Peptide inhibitors of sodium channels Inactive 08-Oct-2014 C07K7/06 0
To view Spyryx Biosciences’s complete patent history, request access »

Spyryx Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spyryx Biosciences FAQs

  • When was Spyryx Biosciences founded?

    Spyryx Biosciences was founded in 2013.

  • Who is the founder of Spyryx Biosciences?

    Robert Tarran Ph.D is the founder of Spyryx Biosciences.

  • Where is Spyryx Biosciences headquartered?

    Spyryx Biosciences is headquartered in Durham, NC.

  • What is the size of Spyryx Biosciences?

    Spyryx Biosciences has 10 total employees.

  • What industry is Spyryx Biosciences in?

    Spyryx Biosciences’s primary industry is Pharmaceuticals.

  • Is Spyryx Biosciences a private or public company?

    Spyryx Biosciences is a Private company.

  • What is Spyryx Biosciences’s current revenue?

    The current revenue for Spyryx Biosciences is 000000.

  • How much funding has Spyryx Biosciences raised over time?

    Spyryx Biosciences has raised $29.1M.

  • Who are Spyryx Biosciences’s competitors?

    Verona Pharma, Theravance Biopharma, The Zambon Group, Edesa Biotech, and Rallybio are some of the 78 competitors of Spyryx Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »